{"id":59613,"date":"2026-03-16T16:16:11","date_gmt":"2026-03-16T08:16:11","guid":{"rendered":"https:\/\/flcube.com\/?p=59613"},"modified":"2026-03-16T16:16:12","modified_gmt":"2026-03-16T08:16:12","slug":"chipscreen-biosciences-cs08399-wins-nmpa-approval-prmt5-mta-inhibitor-targets-mtap-deficient-solid-tumors-and-lymphomas","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59613","title":{"rendered":"Chipscreen Biosciences&#8217; CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas"},"content":{"rendered":"\n<p><strong>Shenzhen Chipscreen Biosciences Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/0512:HKG\">SHA: 688321<\/a>) announced <strong>NMPA clearance<\/strong> to initiate a <strong>clinical study<\/strong> for <strong>CS08399<\/strong>, an <strong>MTA-cooperative PRMT5 inhibitor<\/strong>, in <strong>adult solid tumors and lymphomas with methylthioadenosine phosphorylase (MTAP) deficiency<\/strong>. The <strong>investigational drug<\/strong> selectively targets the <strong>PRMT5-MTA complex<\/strong>, significantly enhancing <strong>PRMT5 inhibition<\/strong> and reducing <strong>symmetric dimethylation of arginine (SDMA)<\/strong> levels to <strong>induce cell cycle arrest and apoptosis<\/strong> in <strong>MTAP-deficient tumor cells<\/strong> while <strong>sparing normal cells<\/strong>, offering a <strong>compelling safety advantage<\/strong> and <strong>synthetic lethality approach<\/strong> to cancer therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>CS08399<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>MTA-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Selective PRMT5-MTA complex targeting; synthetic lethality in MTAP deficiency<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adult solid tumors and lymphomas with MTAP deficiency<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Shenzhen Chipscreen Biosciences (SHA: 688321)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>16\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>CS08399 Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>PRMT5 (protein arginine methyltransferase 5) \u2013 MTA-cooperative binding<\/td><\/tr><tr><td><strong>Synthetic Lethality<\/strong><\/td><td>MTAP deficiency creates dependency on PRMT5-MTA pathway<\/td><\/tr><tr><td><strong>Molecular Action<\/strong><\/td><td>\u2022 Selective inhibition of PRMT5-MTA complex<br>\u2022 Reduces SDMA (symmetric dimethylation of arginine) levels<br>\u2022 Induces cell cycle arrest and apoptosis<\/td><\/tr><tr><td><strong>Selectivity<\/strong><\/td><td><strong>High<\/strong> \u2013 minimal impact on MTAP-normal cells; significant safety advantage<\/td><\/tr><tr><td><strong>Tumor Types<\/strong><\/td><td>Solid tumors and lymphomas with MTAP deficiency (~15% of all cancers)<\/td><\/tr><tr><td><strong>Biomarker<\/strong><\/td><td>MTAP loss (homozygous deletion)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Scientific Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MTAP Deletion:<\/strong> Common in cancers (glioblastoma, pancreatic, lung, bladder, lymphoma); ~15% of all tumors; results in accumulation of MTA (methylthioadenosine)<\/li>\n\n\n\n<li><strong>PRMT5 Addiction:<\/strong> MTA binds and partially inhibits PRMT5; MTAP-deficient cells become hypersensitive to further PRMT5 inhibition<\/li>\n\n\n\n<li><strong>Synthetic Lethality:<\/strong> CS08399 exploits this dependency, killing tumor cells while sparing normal tissue<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>MTAP-Deficient Cancers<\/strong><\/td><td>15% of all cancers (~2.5 million annual cases globally); high unmet need in aggressive tumors<\/td><\/tr><tr><td><strong>PRMT5 Competition<\/strong><\/td><td>Multiple PRMT5 inhibitors in development (GSK3326595, JNJ-64619178, MRTX1719); CS08399 MTA-cooperative mechanism differentiates<\/td><\/tr><tr><td><strong>Synthetic Lethality Trend<\/strong><\/td><td>PARP inhibitors validated approach; MTAP\/PRMT5 next frontier for targeted therapy<\/td><\/tr><tr><td><strong>Chipscreen Innovation<\/strong><\/td><td>Extends company&#8217;s epigenetic drug discovery expertise (chidamide,\u897f\u5965\u7f57\u5c3c); China-first development strategy<\/td><\/tr><tr><td><strong>Biomarker-Driven Strategy<\/strong><\/td><td>MTAP IHC or CDKN2A\/MTAP deletion testing enables patient selection; companion diagnostic development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Status<\/th><th>CS08399 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>GSK<\/strong><\/td><td>GSK3326595<\/td><td>PRMT5 inhibitor (MTA-non-cooperative)<\/td><td>Phase I\/II<\/td><td>MTA-cooperative binding enhances selectivity for MTAP-deficient cells<\/td><\/tr><tr><td><strong>Johnson &amp; Johnson<\/strong><\/td><td>JNJ-64619178<\/td><td>PRMT5 inhibitor<\/td><td>Phase I<\/td><td>Similar mechanism; CS08399 China-first development<\/td><\/tr><tr><td><strong>Mirati<\/strong><\/td><td>MRTX1719<\/td><td>PRMT5 inhibitor (MTA-cooperative)<\/td><td>Phase I\/II<\/td><td>Direct competitor; CS08399 potentially improved selectivity profile<\/td><\/tr><tr><td><strong>Chipscreen<\/strong><\/td><td><strong>CS08399<\/strong><\/td><td><strong>MTA-cooperative PRMT5 inhibitor<\/strong><\/td><td><strong>Phase I-ready<\/strong><\/td><td><strong>Synthetic lethality approach; minimal normal cell impact; China innovation<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>2026-2028<\/td><td>Safety, tolerability, MTD; MTAP-deficient tumor enrichment; SDMA biomarker validation<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>2028-2030<\/td><td>Efficacy signals in MTAP-deleted glioblastoma, pancreatic cancer, lymphoma; combination with chemotherapy or immunotherapy<\/td><\/tr><tr><td><strong>Regulatory Strategy<\/strong><\/td><td>2030-2031<\/td><td>China NDA; U.S.\/EU IND filing; breakthrough therapy designation potential for aggressive tumors<\/td><\/tr><tr><td><strong>Companion Diagnostic<\/strong><\/td><td>2026-2028<\/td><td>MTAP IHC assay development and validation; CDKN2A\/MTAP co-deletion NGS panel<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, synthetic lethality mechanism validation, and competitive positioning for CS08399. Actual results may differ due to PRMT5 biology complexity, MTAP testing adoption, and competitive dynamics with other epigenetic targeted therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688321_20260314_CD3N.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688321_20260314_CD3N.\"><\/object><a id=\"wp-block-file--media-ca9616c0-89c7-44fe-b2be-a5e345d0f552\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688321_20260314_CD3N.pdf\">688321_20260314_CD3N<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688321_20260314_CD3N.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ca9616c0-89c7-44fe-b2be-a5e345d0f552\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced NMPA clearance to initiate a clinical study&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,659,62,1240],"class_list":["post-59613","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-chipscreen-biosciences","tag-clinical-trial-approval-initiation","tag-sha-688321"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chipscreen Biosciences&#039; CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced NMPA clearance to initiate a clinical study for CS08399, an MTA-cooperative PRMT5 inhibitor, in adult solid tumors and lymphomas with methylthioadenosine phosphorylase (MTAP) deficiency. The investigational drug selectively targets the PRMT5-MTA complex, significantly enhancing PRMT5 inhibition and reducing symmetric dimethylation of arginine (SDMA) levels to induce cell cycle arrest and apoptosis in MTAP-deficient tumor cells while sparing normal cells, offering a compelling safety advantage and synthetic lethality approach to cancer therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59613\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chipscreen Biosciences&#039; CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas\" \/>\n<meta property=\"og:description\" content=\"Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced NMPA clearance to initiate a clinical study for CS08399, an MTA-cooperative PRMT5 inhibitor, in adult solid tumors and lymphomas with methylthioadenosine phosphorylase (MTAP) deficiency. The investigational drug selectively targets the PRMT5-MTA complex, significantly enhancing PRMT5 inhibition and reducing symmetric dimethylation of arginine (SDMA) levels to induce cell cycle arrest and apoptosis in MTAP-deficient tumor cells while sparing normal cells, offering a compelling safety advantage and synthetic lethality approach to cancer therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59613\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T08:16:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-16T08:16:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59613#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59613\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chipscreen Biosciences&#8217; CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas\",\"datePublished\":\"2026-03-16T08:16:11+00:00\",\"dateModified\":\"2026-03-16T08:16:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59613\"},\"wordCount\":530,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Chipscreen Biosciences\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688321\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59613#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59613\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59613\",\"name\":\"Chipscreen Biosciences' CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-16T08:16:11+00:00\",\"dateModified\":\"2026-03-16T08:16:12+00:00\",\"description\":\"Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced NMPA clearance to initiate a clinical study for CS08399, an MTA-cooperative PRMT5 inhibitor, in adult solid tumors and lymphomas with methylthioadenosine phosphorylase (MTAP) deficiency. The investigational drug selectively targets the PRMT5-MTA complex, significantly enhancing PRMT5 inhibition and reducing symmetric dimethylation of arginine (SDMA) levels to induce cell cycle arrest and apoptosis in MTAP-deficient tumor cells while sparing normal cells, offering a compelling safety advantage and synthetic lethality approach to cancer therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59613#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59613\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59613#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chipscreen Biosciences&#8217; CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chipscreen Biosciences' CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas - Insight, China&#039;s Pharmaceutical Industry","description":"Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced NMPA clearance to initiate a clinical study for CS08399, an MTA-cooperative PRMT5 inhibitor, in adult solid tumors and lymphomas with methylthioadenosine phosphorylase (MTAP) deficiency. The investigational drug selectively targets the PRMT5-MTA complex, significantly enhancing PRMT5 inhibition and reducing symmetric dimethylation of arginine (SDMA) levels to induce cell cycle arrest and apoptosis in MTAP-deficient tumor cells while sparing normal cells, offering a compelling safety advantage and synthetic lethality approach to cancer therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59613","og_locale":"en_US","og_type":"article","og_title":"Chipscreen Biosciences' CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas","og_description":"Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced NMPA clearance to initiate a clinical study for CS08399, an MTA-cooperative PRMT5 inhibitor, in adult solid tumors and lymphomas with methylthioadenosine phosphorylase (MTAP) deficiency. The investigational drug selectively targets the PRMT5-MTA complex, significantly enhancing PRMT5 inhibition and reducing symmetric dimethylation of arginine (SDMA) levels to induce cell cycle arrest and apoptosis in MTAP-deficient tumor cells while sparing normal cells, offering a compelling safety advantage and synthetic lethality approach to cancer therapy.","og_url":"https:\/\/flcube.com\/?p=59613","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-16T08:16:11+00:00","article_modified_time":"2026-03-16T08:16:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59613#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59613"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chipscreen Biosciences&#8217; CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas","datePublished":"2026-03-16T08:16:11+00:00","dateModified":"2026-03-16T08:16:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59613"},"wordCount":530,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Chipscreen Biosciences","Clinical trial approval \/ initiation","SHA: 688321"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59613#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59613","url":"https:\/\/flcube.com\/?p=59613","name":"Chipscreen Biosciences' CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-16T08:16:11+00:00","dateModified":"2026-03-16T08:16:12+00:00","description":"Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced NMPA clearance to initiate a clinical study for CS08399, an MTA-cooperative PRMT5 inhibitor, in adult solid tumors and lymphomas with methylthioadenosine phosphorylase (MTAP) deficiency. The investigational drug selectively targets the PRMT5-MTA complex, significantly enhancing PRMT5 inhibition and reducing symmetric dimethylation of arginine (SDMA) levels to induce cell cycle arrest and apoptosis in MTAP-deficient tumor cells while sparing normal cells, offering a compelling safety advantage and synthetic lethality approach to cancer therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59613#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59613"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59613#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chipscreen Biosciences&#8217; CS08399 Wins NMPA Approval \u2013 PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59613"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59613\/revisions"}],"predecessor-version":[{"id":59616,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59613\/revisions\/59616"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}